Skip to main content
    S

    SAB Biotherapeutics Inc (SABS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.00
    +0.04 (+1.35%)

    Market Cap: $266.66M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    SAB Biotherapeutics Inc (SABS) Earnings: Report Dates and Results

    Updated Nov 5, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    SAB Biotherapeutics (SABS) is expected to report earnings on Mar 8, 2027. In the quarter ended Sep 30, 2026, SAB Biotherapeutics reported EPS of -$0.24, above the -$0.27 estimate. It beat the EPS estimate in 5 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    38%(8/21)
    Avg Surprise
    -54.78%
    Streak
    2 Q

    Upcoming Estimates

    Reports Mar 8, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$0.25
    Range-$0.30 - -$0.11
    13 analysts
    Revenue Consensus
    N/A
    RangeN/A
    10 analysts
    Reports May 10, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.25
    Range-$0.32 - -$0.21
    3 analysts
    EPS RevisionsNo revisions (30d)
    EPS Estimate DriftChange to current
    90d ago-$0.21-21.3%
    60d ago-$0.21-21.3%
    30d ago-$0.21-21.3%
    7d ago-$0.21-21.3%
    Current-$0.25
    Revenue Consensus
    N/A
    RangeN/A
    5 analysts

    Next Report

    SABS has an expected report date of Mar 8, 2027.

    SABS Earnings Call

    The latest SABS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 21 quarters below that had an estimate, SABS beat 8, missed 12 and matched 1. The widest gap in the table came in the quarter ended Dec 31, 2021, when EPS landed 500.00% below the estimate.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.24-$0.27-$0.32 - -$0.22+11.11%Beat-148.0%52 up, 0 downNov 5, 2026N/A
    Jun 30, 2026-$0.28-$0.29N/A+3.45%BeatN/A30 up, 0 downAug 6, 2026N/A
    Mar 31, 2026-$0.35-$0.21-$0.31 - -$0.11-69.38%MissN/A50 up, 0 downMay 12, 2026N/A
    Dec 31, 2025-$0.41-$0.17-$0.17 - -$0.17-141.18%MissN/A10 up, 1 downMar 9, 2026N/A
    Sep 30, 2025$0.50-$0.46-$1.04 - -$0.14+208.70%BeatN/A61 up, 1 downNov 14, 2025N/A
    Jun 30, 2025-$1.09-$0.82N/A-32.93%MissN/AN/A0 up, 0 downAug 7, 2025N/A
    Mar 31, 2025-$0.56-$1.07N/A+47.66%BeatN/AN/A0 up, 0 downMay 9, 2025N/A
    Dec 31, 2024-$0.98-$1.21-$1.21 - -$1.21+18.93%BeatN/A10 up, 1 downMar 28, 2025$114698
    Sep 30, 2024-$1.12-$1.09-$1.14 - -$1.06-2.75%MissN/A40 up, 0 downNov 6, 2024N/A
    Jun 30, 2024-$0.79-$1.15-$1.24 - -$1.02+31.30%BeatN/A20 up, 0 downAug 8, 2024$263137
    Mar 31, 2024-$1.14-$0.98-$0.98 - -$0.94-16.33%MissN/A20 up, 0 downApr 1, 2024$944575
    Dec 31, 2023-$3.38-$0.62-$0.64 - -$0.60-445.16%MissN/A20 up, 0 downMar 29, 2024$305011
    Sep 30, 2023-$1.01-$1.15-$1.30 - -$1.00+12.17%BeatN/A30 up, 0 downNov 13, 2023$1.27M
    Jun 30, 2023-$1.29-$1.45-$1.60 - -$1.30+11.03%BeatN/A20 up, 0 downAug 21, 2023$85518
    Mar 31, 2023-$1.48-$1.00N/A-48.00%MissN/A11 up, 0 downApr 14, 2023$581101
    Dec 31, 2022-$0.16-$0.16N/A0.00%In lineN/AN/A0 up, 0 downMar 31, 2023$2.16M
    Sep 30, 2022-$1.83-$1.10-$2.30 - -$0.90-66.36%MissN/A20 up, 0 downNov 15, 2022$3.59M
    Jun 30, 2022-$1.50-$1.00N/A-50.00%MissN/A10 up, 0 downAug 10, 2022$6.35M
    Mar 31, 2022-$1.35-$1.10N/A-22.73%Miss-260.7%20 up, 0 downMay 12, 2022$11.80M
    Dec 31, 2021-$0.66-$0.11-$0.18 - -$0.04-500.00%MissN/A32 up, 0 downMar 29, 2022$11.06M
    Sep 30, 2021-$1.20-$0.60-$2.70 - $0.70-100.00%MissN/A30 up, 0 downNov 22, 2021$14.68M
    Jun 30, 2021-$0.03N/AN/AN/AN/AN/AN/AN/AAug 9, 2021$18.21M
    Mar 31, 2021$0.84N/AN/AN/AN/AN/AN/AN/AApr 2, 2021$16.93M
    Last 23 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$1.56, after -$4.03 the year before. It was -$1.05 for the year ended Dec 31, 2021, the oldest of the 5 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$1.56N/A
    Dec 31, 2024-$4.03N/A
    Dec 31, 2023-$7.16N/A
    Dec 31, 2022-$4.84N/A
    Dec 31, 2021-$1.05N/A

    Earnings Calls

    The only earnings call listed below, 2026Q3 for the period ended Sep 30, 2026, runs about 3,300 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,31912

    2026Q3 Earnings Call

    Opening remarks

    Samuel Reich Chief Executive Officer Thank you, operator. Good morning, and thank you to everyone joining us for our third quarter 2026 earnings call. I'm joined today by Lucy To, our Chief Financial Officer, who will review the third quarter financial results. I'm also joined by Eddie Sullivan, our Co-Founder and President, and Alexandra Kropotova, our Chief Medical Officer. As we begin November, we recognize Diabetes Awareness Month and focus attention on the millions of people living with type 1 diabetes. We remain committed to advancing new medicines with the potential to change the course of the disease and improve the lives of those affected. That focus continues to drive our work at SAB BIO, and we're pleased to have you with us today to review the progress we made during the third quarter. We continue to execute on our priorities for SAB-142 with strong momentum in SAFEGUARD enrollment and the FDA granting Fast Track designation to SAB-142 for the treatment of new-onset Stage 3 type 1 diabetes. For context, SAB-142 is a fully human anti-thymocyte immunoglobulin designed to preserve insulin-producing beta cells in order to slow disease progression in autoimmune type 1 diabetes. It was developed using our proprietary Tc Bovine platform, which allows us to generate fully human, multi-specific antibodies without the need for human donors. Because SAB-142 is fully human, it has the potential to overcome key limitations of non-human approaches and enable safe redosing over the long term. We believe SAB-142 represents an opportunity to help people with type 1 diabetes redefine what a Stage 3 diagnosis can mean. SAB-142 is currently being evaluated in two clinical trials, the registrational Phase 2b SAFEGUARD study for those newly diagnosed with Stage 3 T1D and the investigator-led Phase 3 PRISE study for people up to two years from a Stage 3 T1D diagnosis. Let's start with an enrollment update for SAFEGUARD. The performance of our clinical team this quarter has been exemplary. In September, the study's Data Monitoring Committee approved the final step-down to children ages 5 to 11, helping to further accelerate enrollment. We continue to see strong interest in SAFEGUARD from both patients and investigators, and we're excited to share that the adult and adolescent cohorts are now fully enrolled and closed for screening. With that, we are reaffirming our guidance to complete enrollment of SAFEGUARD in Q4, with topline data expected in the second half of '27. Building on that progress, the PRISE study expects to dose the first patients this quarter. There are seven clinical sites planned across the United States, Europe, and the UK.

    Frequently Asked Questions About SABS

    When is SAB Biotherapeutics's next earnings date?

    SAB Biotherapeutics's next earnings report is expected for Mar 8, 2027.

    Did SABS beat earnings estimates last quarter?

    Yes. SAB Biotherapeutics reported EPS of -$0.24 for the quarter ended Sep 30, 2026, above the -$0.27 estimate, a 11.11% surprise.

    What EPS do analysts expect from SABS next quarter?

    The consensus EPS estimate for SAB Biotherapeutics for the quarter ending Dec 31, 2026 is -$0.25 from 13 analysts, with estimates from -$0.30 to -$0.11.

    How often does SABS beat earnings estimates?

    SAB Biotherapeutics beat the EPS estimate in 5 of the last 8 quarters, with an average surprise of +5.80%.